The invention provides a pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases. The pharmaceutical composition comprises 2-(2-benzofuranyl)-2-imidazoline or a pharmaceutically acceptable salt, a hydrate and a solvate thereof as an active ingredient, and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4, 3-e)-1, 2, 4-triazolo (1, 5-c) pyrimidine or a pharmaceutically acceptable salt, a hydrate and a solvate thereof. The invention further provides a combination containing two medicaments and also provides application of the pharmaceutical composition and the pharmaceutical combination in combined treatment of the central nervous system inflammatory demyelinating diseases, and the synergistic treatment effect is obtained.